Key clinical point: An investigational Alzheimer’s drug appears to interact with the gut microbiome.
Major finding: Levels of “good,” butyrate-producing bacteria were higher in patients who responded well to Anavex 2-73. A bacterial family important in gut homeostasis, however, was decreased in those who responded poorly.
Study details: The stool sampling was conducted in 16 patients.
Disclosures: Dr. Missling is the president of Anavex Life Sciences.
Missling C et al. AAIC 2019, Abstract 32260.